Schering Gains British Biotech's Marimastat, Drops U.S. Fareston Marketing
Executive Summary
Schering-Plough will assume all European and U.S. regulatory filings for British Biotech's cancer therapy marimastat under a collaboration announced September 7 to develop and market British Biotech's matrix metalloproteinase inhibitors.